Adverum Biotechnologies, Inc. has announced progress with yet another therapy designed to extend the time between anti-VEGF injections for treatment of wet age-related macular degeneration (wAMD). The company’s Investigational New Drug (IND) application has been approved for a multi-center study of ADVM-022, a novel gene therapy candidate for the treatment of wAMD.
“We are excited to have this IND active for ADVM-022, currently the only intravitreal gene therapy candidate entering the clinic for patients with wet AMD,” said Leone Patterson, interim president and chief executive officer of Adverum Biotechnologies. “We…look forward to initiating the new OPTIC clinical trial in the fourth quarter of this year.”
In a preclinical study, ADVM-022 induced sustained release of Eylea (aflibercept) following a single intravitreal injection, with robust levels of the protein detected in the eye up to 16 months after treatment.
Six leading retinal centers across the United States are expected to participate in the Phase 1 trial, with each patient being followed for a total of 2 years.
Source: Adverum press release